When surgeons remove a kidney tumor, they face a delicate balancing act: cut away the cancer while preserving as much of the ...
When the FLAURA2 trial made headlines by showing that adding chemotherapy to the targeted drug osimertinib extended overall ...
FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases HONG KONG and SHANGHAI and ...
MET-driven progression is associated with poor prognosis, and there remains a significant unmet need for effective and ...
New Data on Germline EGFR T790M and Non-Smoker Lung Cancer Risk / cancer, EGFR gene, epidermal growth factor receptor, ...
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung ...
Multi-omic profiling stratified recurrence risk beyond pathological stage in resected EGFR-mutant lung adenocarcinoma and may refine adjuvant TKI selection.
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug ...
The lab number most people see first tells only half the kidney story.
A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results